New drug combo targets genetic weaknesses in head and neck cancer

NCT ID NCT04997902

First seen Jan 11, 2026 · Last updated May 06, 2026 · Updated 19 times

Summary

This study tested a combination of two drugs, tipifarnib and alpelisib, in 45 adults with advanced head and neck cancer that had spread or come back. The drugs target specific genetic changes in the tumor (HRAS overexpression or PIK3CA mutations/amplification). The main goals were to check safety and find the best dose, while also seeing if the combination could shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HNSCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Dana-Farber Cancer Institute (Head and Neck Cancer Treatment Center)

    Boston, Massachusetts, 02215, United States

  • Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center)

    Baltimore, Maryland, 21231, United States

  • Lake Nona DDU (Florida Cancer Specialists)

    Orlando, Florida, 32827, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • UT Southwestern Medical Center (Harold C. Simmons Comprehensive Cancer Center)

    Dallas, Texas, 75390, United States

  • University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center)

    Baltimore, Maryland, 21201, United States

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, 53792, United States

  • Washington University, School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.